NO20054630L - Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser - Google Patents

Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser

Info

Publication number
NO20054630L
NO20054630L NO20054630A NO20054630A NO20054630L NO 20054630 L NO20054630 L NO 20054630L NO 20054630 A NO20054630 A NO 20054630A NO 20054630 A NO20054630 A NO 20054630A NO 20054630 L NO20054630 L NO 20054630L
Authority
NO
Norway
Prior art keywords
agonists
antagonists
applications
related reagents
methods
Prior art date
Application number
NO20054630A
Other languages
English (en)
Norwegian (no)
Other versions
NO20054630D0 (no
Inventor
Martin Oft
Terrill K Mccianahan
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of NO20054630L publication Critical patent/NO20054630L/no
Publication of NO20054630D0 publication Critical patent/NO20054630D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Pain & Pain Management (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
NO20054630A 2003-03-10 2005-10-07 Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser NO20054630D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45367203P 2003-03-10 2003-03-10
PCT/US2004/007198 WO2004081190A2 (en) 2003-03-10 2004-03-09 Uses of il-23 agonists and antagonists; related reagents

Publications (2)

Publication Number Publication Date
NO20054630L true NO20054630L (no) 2005-10-07
NO20054630D0 NO20054630D0 (no) 2005-10-07

Family

ID=32990805

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054630A NO20054630D0 (no) 2003-03-10 2005-10-07 Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser

Country Status (22)

Country Link
US (4) US7282204B2 (pl)
EP (2) EP2108658B1 (pl)
JP (4) JP4605798B2 (pl)
CN (1) CN1759123B (pl)
AT (1) ATE440864T1 (pl)
AU (2) AU2004219625B9 (pl)
BR (1) BRPI0408247A (pl)
CA (1) CA2518262C (pl)
CL (1) CL2004000467A1 (pl)
CY (1) CY1109468T1 (pl)
DE (1) DE602004022781D1 (pl)
DK (1) DK1601694T3 (pl)
ES (1) ES2330220T3 (pl)
MX (1) MXPA05009717A (pl)
NO (1) NO20054630D0 (pl)
NZ (2) NZ567860A (pl)
PL (1) PL1601694T3 (pl)
PT (1) PT1601694E (pl)
SI (1) SI1601694T1 (pl)
TW (2) TWI357336B (pl)
WO (1) WO2004081190A2 (pl)
ZA (1) ZA200506879B (pl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020137890A1 (en) * 1997-03-31 2002-09-26 Genentech, Inc. Secreted and transmembrane polypeptides and nucleic acids encoding the same
WO2004042009A2 (en) 2002-10-30 2004-05-21 Genentech, Inc. Inhibition of il-17 production
PT1601694E (pt) * 2003-03-10 2009-12-03 Schering Corp Utilizações de agonistas e antagonistas de il-23; reagentes relacionados
WO2004101750A2 (en) * 2003-05-09 2004-11-25 Centocor, Inc. IL-23p40 SPECIFIC IMMUNOGLOBULIN DERIVED PROTEINS, COMPOSITIONS, METHODS AND USES
CN1942201B (zh) * 2004-02-17 2012-06-20 先灵公司 调节il-23活性的方法；相关试剂
US20060193821A1 (en) * 2004-03-05 2006-08-31 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
US20070066550A1 (en) * 2004-03-05 2007-03-22 Diener John L Aptamers to the human IL-12 cytokine family and their use as autoimmune disease therapeutics
AR051444A1 (es) 2004-09-24 2007-01-17 Centocor Inc Proteinas derivadas de inmunoglobulina especifica de il-23p40, composiciones, epitopos, metodos y usos
WO2006068987A2 (en) * 2004-12-20 2006-06-29 Schering Corporation Uses of il-23 antagonists in the treatment of diabetes mellitus
AU2012258409B2 (en) * 2005-06-30 2016-01-07 Centocor, Inc. Anti-IL-23 antibodies, compositions, methods and uses
DK2452694T3 (en) * 2005-06-30 2019-03-04 Janssen Biotech Inc Anti-IL-23 antibodies, compositions, methods and applications
CA2612785A1 (en) * 2005-06-30 2007-01-11 Archemix Corp. Polynucleotides and polypeptides of the il-12 family of cytokines
EA013506B1 (ru) * 2005-08-25 2010-06-30 Эли Лилли Энд Компани Антитело к il-23 и его применение
SG10201402712QA (en) 2005-08-31 2014-08-28 Merck Sharp & Dohme Engineered anti-il-23 antibodies
JP2009507023A (ja) 2005-09-01 2009-02-19 シェーリング コーポレイション 自己免疫性眼炎症性疾患を処置するためのｉｌ−２３およびｉｌ−１７のアンタゴニストの使用
SI1971366T1 (sl) 2005-12-29 2014-10-30 Janssen Biotech, Inc. Humana protitelesa anti-il-23, sestavki, postopki in uporabe
US7910703B2 (en) 2006-03-10 2011-03-22 Zymogenetics, Inc. Antagonists to IL-17A, IL-17F, and IL-23P19 and methods of use
US7790862B2 (en) 2006-06-13 2010-09-07 Zymogenetics, Inc. IL-17 and IL-23 antagonists and methods of using the same
EP1882699A1 (en) * 2006-07-27 2008-01-30 Heinfried Radeke Regulation of interleukin-23
TWI426918B (zh) * 2007-02-12 2014-02-21 Merck Sharp & Dohme Ｉｌ-２３拮抗劑於治療感染之用途
JP2010518858A (ja) 2007-02-23 2010-06-03 シェーリング コーポレイション 操作された抗−ｉｌ−２３ｐ１９抗体
RS58098B1 (sr) 2007-02-23 2019-02-28 Merck Sharp & Dohme Anti-il-23p19 antitela proizvedena genetičkim inženjerstvom
CA2679381A1 (en) 2007-02-28 2008-09-04 Schering Corporation Engineered anti-il-23r antibodies
EP2417974A1 (en) * 2007-02-28 2012-02-15 Schering Corporation Combination therapy for treatment of immune disorders
AU2008273814A1 (en) * 2007-07-06 2009-01-15 Valorisation Hsj, Societe En Commandite IL-23 receptor antagonists and uses thereof
AR068723A1 (es) * 2007-10-05 2009-12-02 Glaxo Group Ltd Proteina que se une a antigenos que se une a il-23 humana y sus usos
JPWO2009054454A1 (ja) 2007-10-24 2011-03-03 国立大学法人 東京医科歯科大学 カテプシン阻害剤を有効成分として含有するＴｏｌｌ様受容体のシグナル伝達の調整剤
KR20170023209A (ko) 2008-05-05 2017-03-02 노비뮨 에스 에이 항-ｉｌ-１７ａ／ｉｌ-１７ｆ 교차-반응성 항체 및 그의 사용 방법
US20110158992A1 (en) * 2008-08-27 2011-06-30 Schering Corporation Engineered Anti-IL-23R Antibodies
US20110183859A1 (en) * 2008-09-25 2011-07-28 The United States Of America, As Represented By The Secretary, Inflammatory genes and microrna-21 as biomarkers for colon cancer prognosis
ES2469802T3 (es) * 2008-10-20 2014-06-20 Valipharma Métodos y usos que implican aberraciones genéticas de NAV 3 y expresión aberrante de múltiples genes
WO2010115786A1 (en) * 2009-04-01 2010-10-14 Glaxo Group Limited Anti-il-23 immunoglobulins
CN102458437B (zh) * 2009-05-05 2015-06-10 诺维莫尼公司 抗il-17f抗体及其使用方法
US20120269765A1 (en) * 2009-07-24 2012-10-25 Garcia K Christopher Cytokine compositions and methods of use thereof
US20110086806A1 (en) * 2009-10-09 2011-04-14 Anaphore, Inc. Polypeptides that Bind IL-23R
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US20110311527A1 (en) 2010-06-16 2011-12-22 Allergan, Inc. IL23p19 ANTIBODY INHIBITOR FOR TREATING OCULAR AND OTHER CONDITIONS
WO2012061448A1 (en) 2010-11-04 2012-05-10 Boehringer Ingelheim International Gmbh Anti-il-23 antibodies
USRE49026E1 (en) 2011-06-14 2022-04-12 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
US8946150B2 (en) 2011-06-14 2015-02-03 Medical Diagnostic Laboratories, LLC. Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
PL3326649T3 (pl) 2012-05-03 2022-04-25 Boehringer Ingelheim International Gmbh Przeciwciała anty-il-23p19
ES2729603T3 (es) 2012-06-27 2019-11-05 Merck Sharp & Dohme Anticuerpos IL-23 antihumanos cristalinos
UA117466C2 (uk) 2012-12-13 2018-08-10 Мерк Шарп Енд Доме Корп. СТАБІЛЬНИЙ СКЛАД У ВИГЛЯДІ РОЗЧИНУ АНТИТІЛА ДО IL-23p19
TWI636063B (zh) 2013-03-08 2018-09-21 美國禮來大藥廠 結合ｉｌ－２３之抗體
US10507241B2 (en) 2014-07-24 2019-12-17 Boehringer Ingelheim International Gmbh Biomarkers useful in the treatment of IL-23A related diseases
EP3189153B1 (en) 2014-09-03 2021-06-16 Boehringer Ingelheim International GmbH Compound targeting il-23a and tnf-alpha and uses thereof
AR102417A1 (es) 2014-11-05 2017-03-01 Lilly Co Eli Anticuerpos biespecíficos anti-tnf- / anti-il-23
SG11201705728RA (en) 2015-02-04 2017-08-30 Boehringer Ingelheim Int Methods of treating inflammatory diseases
JP6871876B2 (ja) * 2015-03-11 2021-05-19 ラッシュ ユニヴァーシティ メディカル センター がんを治療するための組成物と方法
CN110913906A (zh) 2017-05-02 2020-03-24 默沙东公司 抗lag3抗体的制剂和抗lag3抗体与抗pd-1抗体的共制剂
JOP20190260A1 (ar) 2017-05-02 2019-10-31 Merck Sharp & Dohme صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
EP3762015B1 (en) 2018-03-05 2025-12-24 Janssen Biotech, Inc. Guselkumab for use in the treatment of crohn's disease with a dosage regimen
MX2021005394A (es) 2018-11-07 2021-07-06 Merck Sharp & Dohme Llc Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
IL283192B2 (en) 2018-11-20 2025-10-01 Janssen Biotech Inc A safe and effective method for treating psoriasis with a specific anti-IL-23 antibody
MX2021014302A (es) 2019-05-23 2022-01-04 Janssen Biotech Inc Metodo para tratar la enfermedad inflamatoria del intestino con una terapia de combinacion de anticuerpos contra il-23 y tnf alfa.
CA3180340A1 (en) * 2020-04-17 2021-10-21 The Board Of Trustees Of The Leland Stanford Junior University Engineered il-12 and il-23 polypeptides and uses thereof
CN115768466A (zh) 2020-05-21 2023-03-07 詹森生物科技公司 用抗IL-23和TNFα抗体的联合疗法治疗炎性肠病的方法
AU2022369312A1 (en) 2021-10-20 2024-05-02 Synthekine, Inc. Heterodimeric fc cytokines and uses thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6176962B1 (en) 1990-02-28 2001-01-23 Aclara Biosciences, Inc. Methods for fabricating enclosed microchannel structures
US5856457A (en) 1991-03-29 1999-01-05 Genentech, Inc. Nucleic acids encoding a human IL-8 receptor
US6132764A (en) 1994-08-05 2000-10-17 Targesome, Inc. Targeted polymerized liposome diagnostic and treatment agents
US5888530A (en) 1995-07-21 1999-03-30 The General Hospital Corporation Method of enhancing delivery of a pharmaceutical formulation
US6056973A (en) 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6060284A (en) * 1997-07-25 2000-05-09 Schering Corporation DNA encoding interleukin-B30
US5842787A (en) 1997-10-09 1998-12-01 Caliper Technologies Corporation Microfluidic systems incorporating varied channel dimensions
US6326482B1 (en) 1999-04-23 2001-12-04 Genentech, Inc. SH2 domain-containing peptides
DE69942671D1 (de) 1998-12-01 2010-09-23 Facet Biotech Corp Humanisierte antikoerper gegen gamma-interferon
AU780163B2 (en) * 1999-09-09 2005-03-03 Merck Sharp & Dohme Corp. Mammalian interleukin-12 P40 and interleukin B30, combinations thereof, antibodies, uses in pharmaceutical compositions
CN1575337A (zh) * 2000-05-10 2005-02-02 先灵公司 哺乳动物细胞因子受体亚单位蛋白、相关试剂及方法
MXPA03002971A (es) * 2000-10-06 2004-05-05 Immunex Corp Receptores de hematopoyetina hpr1 y hpr2.
US20030157105A1 (en) * 2001-05-30 2003-08-21 Carton Jill M. Anti-p40 immunglobulin derived proteins, compositions, methods and uses
PT1601694E (pt) * 2003-03-10 2009-12-03 Schering Corp Utilizações de agonistas e antagonistas de il-23; reagentes relacionados

Also Published As

Publication number Publication date
AU2004219625B9 (en) 2010-12-23
ATE440864T1 (de) 2009-09-15
SI1601694T1 (sl) 2010-01-29
TW201141521A (en) 2011-12-01
WO2004081190A3 (en) 2005-02-03
CN1759123B (zh) 2011-04-13
US8034341B2 (en) 2011-10-11
ZA200506879B (en) 2006-05-31
NZ567860A (en) 2009-11-27
CA2518262A1 (en) 2004-09-23
TW200505479A (en) 2005-02-16
JP2014005286A (ja) 2014-01-16
AU2004219625A1 (en) 2004-09-23
AU2010212372B2 (en) 2012-12-20
AU2010212372A1 (en) 2010-09-09
EP2108658B1 (en) 2016-06-08
DK1601694T3 (da) 2009-12-14
PL1601694T3 (pl) 2010-02-26
EP2108658A1 (en) 2009-10-14
CA2518262C (en) 2014-05-06
JP2006520781A (ja) 2006-09-14
DE602004022781D1 (de) 2009-10-08
JP2011032275A (ja) 2011-02-17
CL2004000467A1 (es) 2005-05-06
PT1601694E (pt) 2009-12-03
US20120034219A1 (en) 2012-02-09
EP1601694B1 (en) 2009-08-26
US20080057058A1 (en) 2008-03-06
ES2330220T3 (es) 2009-12-07
TWI357336B (en) 2012-02-01
US7282204B2 (en) 2007-10-16
CY1109468T1 (el) 2014-08-13
US20100003251A1 (en) 2010-01-07
TWI439285B (zh) 2014-06-01
WO2004081190A2 (en) 2004-09-23
MXPA05009717A (es) 2005-10-18
HK1076477A1 (en) 2006-01-20
NZ541898A (en) 2008-07-31
CN1759123A (zh) 2006-04-12
JP4605798B2 (ja) 2011-01-05
NO20054630D0 (no) 2005-10-07
AU2004219625B2 (en) 2010-08-19
EP1601694A2 (en) 2005-12-07
US20040223969A1 (en) 2004-11-11
JP2007197453A (ja) 2007-08-09
BRPI0408247A (pt) 2006-03-01

Similar Documents

Publication Publication Date Title
NO20054630L (no) Anvendelser av IL-23-agonister og -antagonister, beslektede reagenser
ZA200606620B (en) Methods of modulating IL-23 activity ; related reagents
BRPI0507808A (pt) métodos de modular a atividade de citocina; reagentes relacionados
CY1112862T1 (el) Θραυσματα μονοσθενους αντισωματος χρησιμα ως θεραπευτικα
NO20073293L (no) Toll-liknende reseptor-3-antagonister, fremgangsmater og anvendelser
NO20052496D0 (no) Selekterte CGRP antagonister, fremgangsmater for fremstilling derav og anvendelse derav som medikamenter.
DE60331355D1 (de) Steuerung für multimedia-sitzungen
DE60327103D1 (de) Darreichungsformen enthaltend einen protonpumphemmer, einen nsaid und einen puffer
DK1553975T3 (da) Optimerede Fc-varianter og fremgangsmåder til generering heraf.
CY1106766T1 (el) Παραγωγα πυριδινης ως αναστολεις raf κινασης
DE602004008589D1 (de) Informationskommunikationssystem, sendevorrichtung, sendeverfahren und computerprogramm
PT1651247E (pt) Tratamento e diagnóstico de neoplasmas utilizando linfopoietina de estroma tímico
IS2641B (is) 3-Fenýl setið pýridóindólón, framleiðsla og meðferðarleg notkun þess.
UY28344A1 (es) Nuevos compuestos
IS2704B (is) Notkun N-(3-metoxý-5-metýlpýrasín-2-ýl)-2-(4-[1,3,4-oxadíasól-2-ýl]fenýl)pýridín-3-súlfónamíðs við meðhöndlun á krabbameini
NO20053659L (no) Katalysatorkombinasjon, isotaktiske polymerer, fremgangsmate for fremstilling av lineaereisotaktiske polymerer, samt anvendeIse av polymerene
ATE312077T1 (de) Peptiddeformylase-hemmer
AU2003304490A1 (en) Peptide deformylase inhibitors
NL1021524A1 (nl) Menginrichting.
AU2002322035A1 (en) Peptide deformylase inhibitors
DE60207384D1 (de) Peptid-deformylase-hemmer
RU2002102825A (ru) 3-дибензоилметилен-7-нитро-2-хиноксалон, проявляющий анальгетическую активность
ITRM20020358A1 (it) Composizione estetico-farmaceutica per applicazione topica, procedimento per la sua produzione e suoi impieghi.
ES1049921Y (es) Dispositivo de escritorio portatil.
ITPV20020004A1 (it) Dispositivo per miscelare o amalgamare vernici, pitture o simili.

Legal Events

Date Code Title Description
CHAD Change of the owner's name or address (par. 44 patent law, par. patentforskriften)

Owner name: MERCK SHARP AND DOHME CORP, US

Free format text: NEW ADDRESS: 126 EAST LINCOLN AVENUE, US-NJ07065 RAHWAY

FC2A Withdrawal, rejection or dismissal of laid open patent application